Analyst Activity – Needham & Company LLC Lowers Its Price Target On NASDAQ:SMMT – Summit Therapeutics (NASDAQ:SMMT) to $27.00

ME Staff
-
0

Analyst Ratings For NASDAQ:SMMT – Summit Therapeutics (NASDAQ:SMMT)

Today, Needham & Company LLC lowered its price target on NASDAQ:SMMT – Summit Therapeutics (NASDAQ:SMMT) to $27.00 per share.

Some recent analyst ratings include

  • 2/13/2018-BTIG Research initiated coverage with a Buy rating.
  • 1/25/2018-HC Wainwright Reiterated Rating of Buy.
  • 1/4/2018-SunTrust Banks initiated coverage with a Buy rating.
  • 10/16/2017-Canaccord Genuity Reiterated Rating of Buy.


    Recent Trading Activity for NASDAQ:SMMT – Summit Therapeutics (NASDAQ:SMMT)
    Shares of NASDAQ:SMMT – Summit Therapeutics closed the previous trading session at 13.58 up +0.21 1.57% with 20489 shares trading hands.